Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-alpha Antibody Use: 35 Years of Experience at a Single Institute in Korea.
- Author:
Sang Mok LEE
1
;
Eon Chul HAN
;
Seung Bum RYOO
;
Heung Kwon OH
;
Eun Kyung CHOE
;
Sang Hui MOON
;
Joo Sung KIM
;
Hyun Chae JUNG
;
Kyu Joo PARK
Author Information
- Publication Type:Original Article
- Keywords: Crohn disease; Reoperation; Azathioprine; Infliximab
- MeSH: Asian Continental Ancestry Group; Azathioprine; Colon; Crohn Disease*; Diagnosis; Follow-Up Studies; Humans; Korea*; Male; Necrosis*; Recurrence; Reoperation*; Retrospective Studies; Risk Factors*; Infliximab
- From:Annals of Coloproctology 2015;31(4):144-152
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Crohn disease is characterized by high rates of recurrence and reoperations. However, few studies have investigated long-term surgical outcomes in Asian populations. We investigated risk factors for reoperation, particularly those associated with anti-tumor necrosis factor-alpha (anti-TNF-alpha) antibody use, and long-term follow-up results. METHODS: We reviewed the records of 148 patients (100 males and 48 females) who underwent surgery for gastrointestinal Crohn disease and retrospectively analyzed long-term outcomes and risk factors. RESULTS: The mean age at diagnosis was 28.8 years. Thirty-eight patients (25.7%) received monoclonal antibody treatment before reoperation. A small bowel and colon resection was most commonly performed (83 patients, 56.1%). The median follow-up was 149 months, during which 47 patients underwent reoperation. The median interval between the primary and the secondary surgeries was 65 months, with accumulated reoperation rates of 16.5%, 31.8%, and 57.2% after 5, 10, and 15 years, respectively. Obstruction was the most common indication for reoperation (37 patients, 25.0%). In a multivariable analysis, age <17 years at diagnosis (A1) (odds ratio [OR], 2.20; P = 0.023), penetrating behavior (B3) (OR, 4.39; P < 0.001), and no azathioprine use (OR, 2.87; P = 0.003) were associated with reoperation. Anti-TNF-alpha antibody use did not affect the reoperation rate (P = 0.767). CONCLUSION: We showed a high reoperation rate regardless of treatment with anti-TNF-alpha antibody, which indicates that recurrent surgery is still needed to cure patients with gastrointestinal Crohn diseases. Younger age at primary operation, penetrating behavior, and no azathioprine use were significant factors associated with reoperation for gastrointestinal Crohn disease.
